What have imaging studies with evolocumab yielded?
Authors:
Tomáš Kovárník 1; Karel Kopřiva 2; Jan Pudil 1; Zhi Chen 3; Milan Šonka 3
Authors‘ workplace:
II. interní klinika kardiologie a angiologie 1. LF UK a VFN v Praze
1; Kardiologie (KAR), Nemocnice Na Homolce, Praha
2; Dept. of Electrical & Computer Engineering and Iowa Institute for Biomedical Imaging, The University of Iowa, Iowa City, IA, USA
3
Published in:
AtheroRev 2022; 7(3): 159-165
Category:
Clinical Studies
Overview
This review describes usual endpoints in trials assessing changes of atherosclerotic plaques during lipid-lowering therapy. Authors focus their attention to the trials using evolocumab as an active drug.
Keywords:
optical coherence tomography – evolocumab – atherosclerosis regression – intravascular ultrasound
Sources
1. Oyama K, Furtado R, Fagundes A et al. Effect of Evolocumab on Complex Coronary Requiring Revascularization. J Am Coll Cardiol 2021; 77(3): 259–267. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.11.011>.
2. Sabatine M, Giugliano R, Keech A et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
3. Nicholls SJ, Hsu A, Wolski K et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010; 55(21): 2399–2407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.02.026>.
4. Bhindi R, Guan M, Zhao Y et al. Coronary atheroma regression and adverse cardiac events: a systematic review and meta-regression analysis. Atherosclerosis 2019; 284: 194–201. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.03.005>.
5. Mintz GS, Garcia-Gracia HM, Nicholls SJ et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. Eurointervention 2011; 6(9): 1123–1130. Dostupné z DOI: <http://dx.doi.org/10.4244/EIJV6I9A195>.
6. Nicholls S, Puri R, Anderson T et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316(22): 2373–2384. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.16951>.
7. Kovárník T, Kopřiva K, Pudil J. Regrese koronární aterosklerózy a možnosti jejího zobrazení se zaměřením na výsledky studie GLAGOV. [Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial]. Vnitř Lék 2018; 64(1): 61–64.
8. Hougaard M, Hansen HS, Thayssen P et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med 2017; 18: 110–117. Dostupné z DOI: <http://dx.doi.org/10.1016/j.carrev.2016.11.010>.
9. Nozue T, Yamamoto S, Tohyama S et al. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J 2012; 163(2): 191–199.e1. Dostupné z DOI: <http://doi 10.1016/j.ahj.2011.11.004>.
10. Lee SWL, Hau WK, Kong SL et al. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients – The VENUS study. Circ J 2012; 76(11): 2662–2672. Dostupné z DOI: <http://dx.doi.org/10.1253/circj.cj-12–0325>.
11. Puri R, Libby P, Nissen SE et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging 2014; 15(4): 380–388. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjci/jet251>.
12. Kovarnik T, Mintz GS, Skalicka H et al. Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration. Circ J 2012; 76(1):176–183. Dostupné z DOI: <http://dx.doi.org/10.1253/circj.cj-11–0730>.
13. Nair A, Kuban BD, Tuzcu EM et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106(17): 2200–2206. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000035654.18341.5e>.
14. Yano H, Horinaka S, Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol 2020; 75(3): 289–295. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jjcc.2019.08.002>.
15. Kassis N, Kovarnik T, Chen Z et al. Fibrous Cap Thickness Predicts Stable Coronary Plaque Progression: Early Clinical Validation of a Semiautomated OCT Technology. JSCAI (Journal of the Society for Cardiovascular Angiography & Intervention) 2022. In press. Dostupné z DOI: <https://doi.org/10.1016/j.jscai.2022.100400>.
16. Nicholls S, Kataoka Y, Nissen S et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging 2022; 15(7): 1308–1321. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2022.03.002>.
17. Gao F, Wang ZJ, Ma XT et al. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography. Lipids Health Dis 2021; 20(1): 106. Dostupné z DOI: <http://dx.doi.org/10.1186/s12944–021–01528–3>.
18. Zanchin Ch, Koskinas K, Ueki Y et al. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial. Am Heart J 2021; 238: 33–44. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2021.04.006>.
19. Otake H, Sugizaki Y, Toba T et al. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. J Cardiol 2019; 73(3): 228–232. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jjcc.2018.11.012>.
20. Rioufol G, Finet G, Ginon I et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome a three-vessel intravascular ultrasound study. Circulation 2002; 106(4): 804–808. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000025609.13806.31>. Retraction in Notice of retraction. Circulation 2012; 125(23): e1019. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0b013e31825f643c>.
21. Nicholls S, Tuzcu M, Sipahi I et al. Relationship between atheroma regression and change in lumen size after infusion of Apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47: 992–997.
22. Arbad-Zadeh A, Fuster V. From detecting the vulnerable plaque to managing the vulnerable patient. JACC 2019; 74(12): 1582–1593. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.07.062>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2022 Issue 3
Most read in this issue
- Bempedoic acid – a new drug to lower LDL-cholesterol level
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin
- Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies
- Profesor Zdeněk Zadák pětaosmdesátiletý!